CALCITONIN GENE-RELATED PEPTIDE RECEPTOR ANTAGONIST
Qulipta is a prescription drug approved by the U.S. Food and Drug Administration (FDA) for the preventive treatment of migraine in adults. Qulipta is also referred to by its drug name, atogepant.
Qulipta is a calcitonin gene-related peptide (CGRP) receptor antagonist. CGRP is a substance that dilates blood vessels and contributes to pain signals and inflammation. Quilipta works by binding to the receptor where CGRP usually docks so there’s no more room for CGRP to bind and trigger migraine. This mechanism of action can help some people have less frequent migraine attacks.
How do I take it?
Prescribing information states that Qulipta is available as oral tablets.
The FDA-approved label for Qulipta lists common side effects including fatigue, dizziness, constipation, and nausea.
For more details about this treatment, visit:
Atogepant — MedlinePlus